Navigation Links
Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709

An oral formulation of iclaprim has successfully completed three Phase I trials: a radiolabelled ADME study (absorption, distribution, metabolism and excretion), a Phase I bioavailability trial with a solution and one with a capsule formulation. Arpida believes that the availability of an oral formulation could potentially fulfil an important clinical medical need for the treatment of serious bacterial infections, particularly those caused by MRSA. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge and outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's third most advanced programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against 611 pneumococcal clinical isolates from Europe, the USA and Asia irrespective of the mechanisms of resistance to currently used drugs. Arpida received authorisation to enter first-in-man studies with AR-709 in the UK in the second half of 2006.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating MRSA in preclinical models of skin infection and nasal carriage.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida Announces Promising Results First Man Studies With
(Date:8/21/2014)... SAN JOSE, Calif. , Aug. 21, 2014 /PRNewswire/ ... a medical device company that pioneered the use of ... surgical (MIS) device indicated for fusion of the sacroiliac ... ) published an update to its Lumbar Fusion ... MIS SI joint fusion procedure.  The policy states that ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Indiana blocked the sale of ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... candidate, has been granted orphan drug designation from the ... of pediatric Clostridium difficile infection (CDI).  This ... covers all formulations of fidaxomicin used to treat ...
... 2011 ULURU Inc. (NYSE Amex: ULU), ... a portfolio of wound management and oral care products, today ... 5,000,000 shares of its common stock at a price per ... an institutional investor, resulting in gross proceeds of approximately $500,000. ...
Cached Medicine Technology:Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 2Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 3Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 4ULURU Inc. to Raise $500,000 in Registered Direct Offering 2
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... combination of therapy and antidepressants appears to best help ... reports. Four out of five people suffering from ... recovery when treated with cognitive therapy plus antidepressant medication, ... didn,t work much better than drugs alone in helping ...
(Date:8/21/2014)... 2014 Seattle, WA chiropractors Dr. ... Eastlake Chiropractic and Massage Center have recently welcomed ... Rina Lang, LMP and Mike Larios, LMP have ... massage techniques, and have developed their expertise working in ... particularly important in a clinical environment where massage is ...
(Date:8/21/2014)... August 21, 2014 The results of ... in The Journal of the American Medical Association (JAMA) ... cancers and reduces unnecessary recalls. Memorial Healthcare System was ... study. , “This study confirms what we already know ... cancers we want to find and, at the same ...
(Date:8/21/2014)... The second bellwether trial involving ... has begun in Massachusetts state court. The device ... Law Group LLP, a national personal injury law ... stemming from the implantation of mesh products, provides ... injuries suffered at http://www.wehelpwomen.com/transvaginal-mesh/ . , Maria ...
(Date:8/21/2014)... The Swedish-American Life Science Summit, (SALSS) ... on the Future of Medicine and the challenges ... , With the mission to turn new sciences ... business and science. "Over the years SALSS has ... diverse community with representatives challenging the boundaries of ...
Breaking Medicine News(10 mins):Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2
... , , , ... DST Health Solutions, a leading provider of software and services ... certification, a designation demonstrating its commitment to quality product development. ... Registrar, an independent auditing firm, for meeting the guidelines set ...
... LEBANON, Tenn., July 28 Health Connect Partners, Inc. ( ... the title sponsor of its 2009 Fall Hospital Pharmacy Conference. ... up to 200 directors of pharmacy from some of the largest ... sessions led by healthcare industry experts, the Hospital Pharmacy Conference will ...
... COLORADO SPRINGS, Colo., July 28 Now that summer is in ... across the county. , , With millions enjoying their ... for home pool and hot tub safety is urgent. , , ... home pool and hot tub owners to make safety their priority by following ...
... , WILTON, Conn., July 28, ... Friday, July 24 and Saturday, July 25 in Chicago, Eucerin was ... incidental sun exposure and give them a glimpse into their skin,s ... year marked Eucerin,s first appearance at the annual BlogHer Conference, connecting ...
... , CHICAGO, July 28 When at the pool ... the harmful rays of the sun. But do we remember to apply sunscreen to ... on the feet from unprotected sun exposure, and overlook applying sunscreen to the area. ... of the foot is prevalent and can even be fatal if not caught early. ...
... Mylan Inc. (Nasdaq: MYL ) today reported that in ... proactively and as a courtesy had contacted the U.S. Food and ... a recent news article. As a result, the FDA visited the ... the baseless accusations in the article were unfounded. The FDA noted ...
Cached Medicine News:Health News:DST Health Solutions Achieves ISO 9001:2008 Certification 2Health News:Cardinal Health Announced as Title Sponsor of the Health Connect Partners' 2009 Fall Hospital Pharmacy Conference 2Health News:Seven Tips for Safer Home Swimming Pools and Hot Tubs 2Health News:Eucerin Provides BlogHer Attendees With a Glimpse Into Their Skin's Future With Proprietary 'Time Machine' Aging Simulator 2Health News:Sunscreen on Your Feet? Doctors Urge Sunscreen Use and Exams to Prevent Skin Cancer on Feet 2Health News:Mylan Reports That the FDA Determined That All Accusations Were Unfounded 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: